

## Table of Content

|                                                                                                                           |           |
|---------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>1. INTRODUCTION .....</b>                                                                                              | <b>1</b>  |
| 1.1. INFLUENZA A VIRUSES .....                                                                                            | 1         |
| 1.1.1. <i>Classification, genome, and structure</i> .....                                                                 | 1         |
| 1.1.2. <i>Influenza viruses replication cycle</i> .....                                                                   | 1         |
| 1.1.3. <i>Pathogenicity of avian influenza H5N1 in humans</i> .....                                                       | 2         |
| 1.1.4. <i>Epidemiology of influenza viruses</i> .....                                                                     | 6         |
| 1.2. ANTIVIRAL DRUGS FOR INFLUENZA VIRUSES .....                                                                          | 8         |
| 1.2.1. <i>License antiviral drugs</i> .....                                                                               | 9         |
| 1.2.2. <i>Development of antiviral compounds</i> .....                                                                    | 11        |
| 1.3. TARGETING THE HOST TO INHIBIT INFLUENZA VIRUSES INFECTION .....                                                      | 13        |
| 1.3.1. <i>Influenza virus entry</i> .....                                                                                 | 13        |
| 1.3.2. <i>Influenza viral replication</i> .....                                                                           | 14        |
| 1.3.3. <i>Influenza viruses induced intracellular signalling pathways</i> .....                                           | 15        |
| 1.3.3.1. <i>PI3K/AKT pathway</i> .....                                                                                    | 15        |
| 1.3.4. <i>Immunomodulatory approaches</i> .....                                                                           | 17        |
| 1.3.5. <i>Combination treatment</i> .....                                                                                 | 19        |
| 1.4. THE FLAVONOIDS .....                                                                                                 | 19        |
| 1.4.1. <i>Origin and chemical structure</i> .....                                                                         | 19        |
| 1.4.2. <i>Classification</i> .....                                                                                        | 20        |
| 1.4.3. <i>Biological activities</i> .....                                                                                 | 21        |
| 1.4.4. <i>Biochanin A</i> .....                                                                                           | 23        |
| 1.4.5. <i>Boicalcain</i> .....                                                                                            | 23        |
| 1.5. PURPOSE OF STUDY .....                                                                                               | 24        |
| <b>2. MATERIALS AND METHODS .....</b>                                                                                     | <b>25</b> |
| 2.1. MATERIALS .....                                                                                                      | 25        |
| 2.1.1. <i>Chemicals</i> .....                                                                                             | 25        |
| 2.1.2. <i>Buffers, solutions and culture media</i> .....                                                                  | 26        |
| 2.1.3. <i>Antibodies and Chromogens</i> .....                                                                             | 31        |
| 2.1.4. <i>Commercial reagents and Assay kit</i> .....                                                                     | 32        |
| 2.1.5. <i>Cell lines and primary cell culture</i> .....                                                                   | 32        |
| 2.1.6. <i>Influenza strains</i> .....                                                                                     | 33        |
| 2.1.7. <i>Flavonoids</i> .....                                                                                            | 33        |
| 2.1.8. <i>Antiviral drugs and anti-inflammatory agents</i> .....                                                          | 36        |
| 2.1.9. <i>Software</i> .....                                                                                              | 37        |
| 2.1.10. <i>BSL3 laboratory</i> .....                                                                                      | 37        |
| 2.2. METHODS .....                                                                                                        | 37        |
| 2.2.1. <i>Cell culture preparation</i> .....                                                                              | 37        |
| 2.2.2. <i>Primary cell culture</i> .....                                                                                  | 37        |
| 2.2.3. <i>Virus stock preparation</i> .....                                                                               | 39        |
| 2.2.4. <i>Virus infection</i> .....                                                                                       | 39        |
| 2.2.5. <i>Standard end point titration assay</i> .....                                                                    | 39        |
| 2.2.6. <i>Cell viability assay</i> .....                                                                                  | 40        |
| 2.2.7. <i>Antigen reduction assay</i> .....                                                                               | 42        |
| 2.2.8. <i>Immunohistochemistry staining</i> .....                                                                         | 42        |
| 2.2.9. <i>Cytotoxicity dose 50 (CC<sub>50</sub>), inhibitory dose 50 (IC<sub>50</sub>) and selective index (SI)</i> ..... | 42        |
| 2.2.10. <i>Virus yield reduction assay</i> .....                                                                          | 43        |
| 2.2.11. <i>Enzyme-Linked Immunosorbent Assay (ELISA)</i> .....                                                            | 43        |

|           |                                                                                                                                                    |            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 2.2.12.   | Cell free caspase-3 enzyme inhibition assay.....                                                                                                   | 45         |
| 2.2.13.   | Immunofluorescence staining .....                                                                                                                  | 46         |
| 2.2.14.   | Protein extraction and western blot analysis .....                                                                                                 | 47         |
| 2.2.15.   | Neuraminidase inhibition (NA) assay .....                                                                                                          | 50         |
| 2.2.16.   | Reactive oxygen species (ROS) production assay .....                                                                                               | 50         |
| 2.2.17.   | Statistical analysis .....                                                                                                                         | 51         |
| <b>3.</b> | <b>RESULTS .....</b>                                                                                                                               | <b>52</b>  |
| 3.1.      | SELECTION OF POTENT FLAVONOIDS WITH H5N1 INFLUENZA A VIRUSES ANTIMVIRAL ACTIVITIES .....                                                           | 52         |
| 3.1.1.    | Effects of the flavonoids to A549 cell viability .....                                                                                             | 52         |
| 3.1.2.    | Screening of the flavonoids for H5N1 influenza A viruses antiviral activities .....                                                                | 52         |
| 3.1.3.    | Cytotoxicity50 (CC <sub>50</sub> ), inhibitory50 (IC <sub>50</sub> ) and selective indices of 22 flavonoids against H5N1 influenza A viruses ..... | 53         |
| 3.1.4.    | Dynamics of biochanin A and baicalein on cellular viability.....                                                                                   | 56         |
| 3.2.      | IDENTIFICATION OF ANTIMVIRAL AND ANTI-INFLAMMATORY OF BIOCHANIN A AND BAICALEIN .....                                                              | 56         |
| 3.2.1.    | Effects of biochanin A and baicalein to H5N1 influenza viral replication in A549 cells .....                                                       | 56         |
| 3.2.2.    | Effects of biochanin A and baicalein on H5N1-induced pro-inflammatory cytokine expression in A549 cell.....                                        | 58         |
| 3.3.      | DETERMINATION OF MOLECULAR MECHANISMS OF BIOCHANIN A AND BAICALEIN AGAINST H5N1 INFLUENZA VIRUS INFECTION.....                                     | 61         |
| 3.3.1.    | Effect of biochanin A and baicalein on H5N1-induced caspase-3 activation.....                                                                      | 61         |
| 3.3.2.    | Effects of biochanin A and baicalein on viral ribonucleoprotein (RNP) complex nuclear transport .....                                              | 62         |
| 3.3.3.    | Effects of biochanin A and baicalein on intracellular signalling proteins .....                                                                    | 64         |
| 3.3.4.    | Effects of biochanin A and baicalein on H5N1 influenza virus neuraminidase (NA) activity .....                                                     | 68         |
| 3.3.5.    | Effect of biochanin A and baicalein to reactive oxygen species (ROS) production .....                                                              | 70         |
| 3.4.      | EFFECTS OF BIOCHANIN A AND BAICALEIN IN COMBINATION TREATMENT .....                                                                                | 72         |
| 3.4.1.    | Combination of biochanin A or baicalein and zanamivir .....                                                                                        | 72         |
| 3.4.2.    | Combination of biochanin A or baicalein and N-acetyl-L-cysteine .....                                                                              | 73         |
| 3.5.      | EFFECTS OF BIOCHANIN A AND BAICALEIN IN MONOCYTE-DERIVED MACROPHAGES (MDMs) .....                                                                  | 76         |
| 3.5.1.    | Effects of biochanin A and baicalein on H5N1 viral replication in MDMs .....                                                                       | 76         |
| 3.5.2.    | Effects of biochanin A and baicalein on cytokine production in MDMs.....                                                                           | 76         |
| 3.5.3.    | Combination treatment of biochanin A and baicalein and NAC in MDMs .....                                                                           | 77         |
| 3.6.      | EFFECT OF BIOCHANIN A AND BAICALEIN ON H5N1 INFLUENZA A/VIETNAM/1203/04 (A/VN/04) .....                                                            | 80         |
| <b>4.</b> | <b>DISCUSSION.....</b>                                                                                                                             | <b>83</b>  |
| <b>5.</b> | <b>CONCLUSION .....</b>                                                                                                                            | <b>91</b>  |
|           | <b>REFERENCES.....</b>                                                                                                                             | <b>101</b> |
| <b>6.</b> | <b>SUPPLEMENTARY DATA.....</b>                                                                                                                     | <b>116</b> |
| 6.1.      | SUPPLEMENTARY 1: FLAVONOIDS WITH NA INHIBITORY POTENTIALS.....                                                                                     | 116        |
| 6.2.      | SUPPLEMENTARY DATA 2: CELLULAR VIABILITY ASSAYS AND THEIR VALIDITIES .....                                                                         | 118        |
|           | <b>ABBREVIATION LIST .....</b>                                                                                                                     | <b>120</b> |
|           | <b>FIGURE LEGENDS .....</b>                                                                                                                        | <b>122</b> |
|           | <b>TABLES.....</b>                                                                                                                                 | <b>124</b> |
|           | <b>PUBLICATIONS .....</b>                                                                                                                          | <b>125</b> |
|           | <b>CURRICULUM VITAE.....</b>                                                                                                                       | <b>126</b> |
|           | <b>DECLARATION .....</b>                                                                                                                           | <b>128</b> |